DOCSLIB.ORG

Antibiotic Codes Used from Drug Programs Information Network

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibiotic Codes Used from Drug Programs Information Network Antibiotic Codes Used from Drug Programs Information Network (DPIN) Database Drug Identification Equivalent Generic Product Name Product Description Anatomical Therapeutic Chemical (ATC) Drug Classification Number (DIN) ERYTHROMYCIN ETHYLSUCCINATE 299 EES 200 GRANULES FOR ORAL SUS J01FA01 ERYTHROMYCIN MINOCYCLINE HCL 14591 MINOCIN 100MG CAP J01AA08 MINOCYCLINE VANCOMYCIN HCL. 15423 VANCOCIN I V AMPOULE 657 500MG J01XA01 VANCOMYCIN ERYTHROMYCIN ESTOLATE 15474 ILOSONE LIQUID 125MG/5ML J01FA01 ERYTHROMYCIN CEPHALEXIN 15547 KEFLEX 125MG/5ML PWS J01DA01 CEFALEXIN PENICILLIN V POT 18740 NADOPEN V TAB 500000IU J01CE02 PHENOXYMETHYLPENICILLIN AMPICILLIN 20877 NOVO-AMPICILLIN J01CA01 AMPICILLIN AMPICILLIN 20885 NOVO-AMPICILLIN J01CA01 AMPICILLIN ERYTHROMYCIN ESTOLATE 20966 NOVO-RYTHRO ESTOLATE CAP 250MG J01FA01 ERYTHROMYCIN TETRACYCLINE HYDROCHLORIDE 21059 NOVO-TETRA 250MG J01AA07 TETRACYCLINE AMPICILLIN 21148 NOVO-AMPICILLIN J01CA01 AMPICILLIN ERYTHROMYCIN ESTOLATE 21172 NOVO-RYTHRO ESTOLATE SUS 125MG J01FA01 ERYTHROMYCIN PENICILLIN V POTASSIUM 21202 NOVO-PEN-VK 500 TAB J01CE02 PHENOXYMETHYLPENICILLIN METRONIDAZOLE 21555 NOVO-NIDAZOL TAB 250MG J01XD01 METRONIDAZOLE TETRACYCLINE HYDROCHLORIDE 21806 NOVO-TETRA 250MG J01AA07 TETRACYCLINE TETRACYCLINE HYDROCHLORIDE 24422 TETRACYN CAP 250MG J01AA07 TETRACYCLINE CLINDAMYCIN HCL 30570 DALACIN C 150 MG CAP J01FF01 CLINDAMYCIN CEPHALEXIN 35645 KEFLEX 250 ORAL SUSP J01DA01 CEFALEXIN TETRACYCLINE HYDROCHLORIDE 151416 NOVO-TETRA SUS 125MG/5ML J01AA07 TETRACYCLINE PENICILLIN G POTASSIUM 151432 NOVO-PEN G 500 J01CE01 BENZYLPENICILLIN ERYTHROMYCIN ESTOLATE 210641 ILOSONE LIQUID 250MG/5ML J01FA01 ERYTHROMYCIN GENTAMICIN SULFATE 40MG/ML INJ 223824 GARAMYCIN INJ 40MG/ML J01GB03 GENTAMICIN CLINDAMYCIN-2-PALMITATE HCL 225851 DALACIN C PALMITATE FLAVORED G J01FF01 CLINDAMYCIN CEPHALEXIN 244392 KEFLEX 500MG TAB J01DA01 CEFALEXIN ERYTHROMYCIN BASE 244635 ERYTHROMID TAB 250MG J01FA01 ERYTHROMYCIN PENICILLIN V ((AS BENZATINE 247359 PEN- VEE SUS 180MG J01CE10 BENZATHINE PHENOXYMETHYLPENICILLIN PENICILLIN V POT 251631 NADOPEN V 400 J01CE02 PHENOXYMETHYLPENICILLIN CLINDAMYCIN PHOSPHATE 260436 DALACIN C PHOSPHATE J01FF01 CLINDAMYCIN ERYTHROMYCIN ESTOLATE 262595 NOVO-RYTHRO ESTOLATE SUS J01FA01 ERYTHROMYCIN SULFAMETHOXAZOLE/TRIMETHOPRIM 270636 SEPTRA TAB J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM 270644 SEPTRA PEDIATRIC SUS J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM 272485 BACTRIM ROCHE SUSPENSION PAEDI J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM MINOCYCINE HCL 282308 MINOCIN CAP 50MG J01AA08 MINOCYCLINE AMOXICILLIN 288497 AMOXIL 250MG CAP J01CA04 AMOXICILLIN AMOXICILLIN 288500 AMOXIL 125 ORAL SUS 125MG/ML J01CA04 AMOXICILLIN AMOXICILLIN 288519 AMOXIL 250 ORAL SUSPENSION J01CA04 AMOXICILLIN TOBRAMYCIN SULFATE 325449 NEBCIN INJ 40MG/ML J01GB01 TOBRAMYCIN TOBRAMYCIN SULFATE 325457 NEBCIN INJ 10MG/ML J01GB01 TOBRAMYCIN AMOXICILLIN 330531 AMOXIL CAP 500MG J01CA04 AMOXICILLIN CLOXACILLIN SODIUM 337757 NOVO-CLOXIN FOR ORAL SOLUTION J01CF02 CLOXACILLIN CLOXACILLIN SODIUM 337765 NOVO-CLOXIN CAP 250MG J01CF02 CLOXACILLIN CLOXACILLIN SODIUM 337773 NOVO-CLOXIN CAP 500MG J01CF02 CLOXACILLIN CEPHALEXIN 342084 NOVO-LEXIN 250MG CAP J01DA01 CEFALEXIN CEPHALEXIN 342092 NOVO-LEXIN 250MG/5ML PWS J01DA01 CEFALEXIN CEPHALEXIN 342106 NOVO-LEXIN 125MG/5ML PWS J01DA01 CEFALEXIN CEPHALEXIN 342114 NOVO-LEXIN 500MG CAP J01DA01 CEFALEXIN SULFAMETHOXAZOLE/TRIMETHOPRIM 368040 SEPTRA DS TAB J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM 371823 BACTRIM DS ROCHE TAB J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM Antibiotic Codes Used from Drug Programs Information Network (DPIN) Database Drug Identification Equivalent Generic Product Name Product Description Anatomical Therapeutic Chemical (ATC) Drug Classification Number (DIN) ERYTHROMYCIN STEARATE 391581 NOVO-RYTHRO STEARATE TAB 250MG J01FA01 ERYTHROMYCIN PENICILLIN V POT 391603 NOVO-PEN VK SYR 500000/5ML J01CE02 PHENOXYMETHYLPENICILLIN AMOXICILLIN 406716 NOVAMOXIN CAP 500MG J01CA04 AMOXICILLIN AMOXICILLIN 406724 NOVAMOXIN CAP 250MG J01CA04 AMOXICILLIN SULFAMETHOXAZOLE/TRIMETHOPRIM 445266 APO-SULFATRIM PEDIATRIC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM 445274 APO-SULFATRIM TAB J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM 445282 APO-SULFATRIM DS TAB J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM AMOXICILLIN 452130 NOVAMOXIN SUS 250MG/5ML J01CA04 AMOXICILLIN AMOXICILLIN 452149 NOVAMOXIN SUS 125MG/5ML J01CA04 AMOXICILLIN ERYTHROMYCIN ETHYLSUCCINATE 453617 EES-400 GRANULES FOR ORAL SUS J01FA01 ERYTHROMYCIN CEFACLOR 465186 CECLOR PULVULE 250MG J01DA08 CEFACLOR CEFACLOR 465208 CECLOR 125 PWS J01DA08 CEFACLOR CEFACLOR 465216 CECLOR 250 PWS J01DA08 CEFACLOR COLISTIMETHATE SODIUM 476420 COLY-MYCIN M PARENTERAL J01XB01 COLISTIN CEFADROXIL 507245 DURICEF CAP 500MG J01DA09 SULFAMETHOXAZOLE/TRIMETHOPRIM 510637 NOVO-TRIMEL TAB J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM 510645 NOVO-TRIMEL DS TAB J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM METRONIDAZOLE 545066 APO METRONIDAZOLE TAB 250MG J01XD01 METRONIDAZOLE ERYTHROMYCIN STEARATE 545678 APO ERYTHRO S TAB 250MG J01FA01 ERYTHROMYCIN PIPERACILLIN SOD 564982 PIPRACIL INJ 3GM/VIAL J01CA12 PIPERACILLIN TETRACYCLINE HYDROCHLORIDE 580929 APO TETRA CAP 250MG J01AA07 TETRACYCLINE ERYTHROMYCIN/SULFISOXAZOLE 583405 PEDIAZOLE J01RA02 SULFONAMIDES,COMB.WITH OTHER ANTIBACT.EXCL.TRIMET. CEPHALEXIN 583413 NOVO-LEXIN TAB 250MG J01DA01 CEFALEXIN CEPHALEXIN 583421 NOVO-LEXIN TAB 500MG J01DA01 CEFALEXIN ERYTHROMYCIN ETHYLSUCCINATE 583782 EES 600 TAB 600MG J01FA01 ERYTHROMYCIN AMPICILLIN 603260 APO-AMPI J01CA01 AMPICILLIN AMPICILLIN 603279 APO-AMPI J01CA01 AMPICILLIN AMPICILLIN 603287 APO-AMPI J01CA01 AMPICILLIN AMPICILLIN 603295 APO-AMPI J01CA01 AMPICILLIN ERYTHROMYCIN ETHYLSUCCINATE 605859 NOVO-RYTHRO ETHYLSUCCINATE PWS J01FA01 ERYTHROMYCIN ERYTHROMYCIN ENTERIC 607142 ERYC ECC 250MG J01FA01 ERYTHROMYCIN AMOXICILLIN & CLAVULANIC ACID 617490 CLAVULIN-250MG TAB J01CR02 AMOXICILLIN AND ENZYME INHIBITOR AMOXICILLIN & CLAVULANIC ACID 617512 CLAVULIN-125F SUSP J01CR02 AMOXICILLIN AND ENZYME INHIBITOR AMOXICILLIN & CLAVULANIC ACID 617520 CLAVULIN-250F SUSP J01CR02 AMOXICILLIN AND ENZYME INHIBITOR CLOXACILLIN SODIUM 618284 APO CLOXI CAP 500MG J01CF02 CLOXACILLIN CLOXACILLIN SODIUM 618292 APO CLOXI CAP 250MG J01CF02 CLOXACILLIN AMOXICILLIN 628115 APO-AMOXI CAP 250MG J01CA04 AMOXICILLIN AMOXICILLIN 628123 APO-AMOXI CAP 500MG J01CA04 AMOXICILLIN AMOXICILLIN TRIHYDRATE 628131 APO-AMOXI PWR FOR SUSP 125MG/5 J01CA04 AMOXICILLIN AMOXICILLIN 628158 APO-AMOXI PWR FOR SUSP 250MG/5 J01CA04 AMOXICILLIN ERYTHROMYCIN ETHYLSUCCINATE 637416 APO ERYTHRO ES TAB 600MG J01FA01 ERYTHROMYCIN PENICILLIN V POTASSIUM 642215 APO PEN VK TAB 500000UNIT USP J01CE02 PHENOXYMETHYLPENICILLIN PENICILLIN V POTASSIUM 642223 APO PEN VK PWS 200000UNIT/5ML J01CE02 PHENOXYMETHYLPENICILLIN PENICILLIN V POTASSIUM 642231 APO PEN VK PWS 500000UNIT/5ML J01CE02 PHENOXYMETHYLPENICILLIN NORFLOXACIN 643025 NOROXIN TAB 400MG J01MA06 NORFLOXACIN CLOXACILLIN SODIUM 644633 APO CLOXI FOR ORAL SOLN 125MG/ J01CF02 CLOXACILLIN ERYTHROMYCIN ETHYLSUCCINATE 652318 NOVO-RYTHRO ETHYLSUCCINATE 400 J01FA01 ERYTHROMYCIN CEFTRIAXONE DISODIUM 657387 ROCEPHIN PWS INJ 0.25GM/VIAL J01DA13 CEFTRIAXONE Antibiotic Codes Used from Drug Programs Information Network (DPIN) Database Drug Identification Equivalent Generic Product Name Product Description Anatomical Therapeutic Chemical (ATC) Drug Classification Number (DIN) CEFTRIAXONE DISODIUM 657409 ROCEPHIN PWS 2GM/VIAL J01DA13 CEFTRIAXONE CEFTRIAXONE DISODIUM 657417 ROCEPHIN PWS 1GM/VIAL J01DA13 CEFTRIAXONE TRIMETHOPRIM 675229 PROLOPRIM TAB 100MG J01EA01 TRIMETHOPRIM TRIMETHOPRIM 677590 PROLOPRIM 200 TAB 200MG J01EA01 TRIMETHOPRIM ERYTHROMYCIN BASE 682020 APO-ERYTHRO-BASE TAB 250MG J01FA01 ERYTHROMYCIN ERYTHROMYCIN STEARATE 688568 APO-ERYTHRO-S TAB 500MG J01FA01 ERYTHROMYCIN AMOXICILLIN 125MG CHEW TAB 714887 AMOXIL 125MG CHEW TAB J01CA04 AMOXICILLIN AMOXICILLIN 250MG CHEW TAB 714895 AMOXIL CHEW TAB 250MG J01CA04 AMOXICILLIN CLOXACILLIN SOD 717584 NU-CLOXI CAPSULES 250MG J01CF02 CLOXACILLIN DOXYCYLINE 100MG CAP 725250 NOVO-DOXYLIN CAP 100MG J01AA02 DOXYCYCLINE SULFAMETHOXAZOLE/TRIMETHOPRIM 726540 NOVO-TRIMEL ORAL SUS J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM ERYTHROMYCIN ENTERIC 726672 APO-ERYTHRO E-C CAP 250MG J01FA01 ERYTHROMYCIN DOXYCYCLINE 100MG CAP 740713 APO-DOXY CAP 100MG J01AA02 DOXYCYCLINE CEPHALEXIN 768715 APO-CEPHALEX TAB 500MG J01DA01 CEFALEXIN CEPHALEXIN 768723 APO-CEPHALEX TAB 250MG J01DA01 CEFALEXIN ERYTHROMYCIN 769991 PCE TAB 333MG J01FA01 ERYTHROMYCIN METRONIDAZOLE 500MG CAP 783137 TRIKACIDE CAP 500MG J01XD01 METRONIDAZOLE DOXYCYCLINE 100MG CAP 817120 DOXYCIN CAP 100MG J01AA02 DOXYCYCLINE CIPROFLOXACIN HCL 817163 CIPRO TAB 250MG J01MA02 CIPROFLOXACIN CIPROFLOXACIN HCL 817171 CIPRO TAB 500MG J01MA02 CIPROFLOXACIN CEPHALEXIN 250MG TAB 828858 CEPHALEXIN TAB 250MG J01DB01 CEPHALEXIN 500MG TAB 828866 CEPHALEXIN TAB 500MG J01DA01 CEFALEXIN CEFACLOR 832804 CECLOR 375 PWS J01DA08 CEFACLOR SULFAMETHOXAZOLE/TRIMETHOPRIM 846465 APO-SULFATRIM ORAL SUS J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOXYCYCLINE 100MG CAP 860751 DOXYCIN TAB 100MG J01AA02 DOXYCYCLINE AMOXICILLIN 865540 NU-AMOXI SUS 125/5ML J01CA04 AMOXICILLIN AMOXICILLIN 865559 NU-AMOXI SUS 250ML/5ML J01CA04 AMOXICILLIN AMOXICILLIN 865567 NU-AMOXI CAP 250MG J01CA04 AMOXICILLIN AMOXICILLINE 865575 NU-AMOXI CAP 500MG J01CA04 AMOXICILLIN SULFAMETHOXAZOLE & TRIMETHOPR 865710 NU-COTRIMOX TAB
Load more

Recommended publications
  • Cefalexin in the WHO Essential Medicines List for Children Reject
    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
    [Show full text]
  • Medicines to Treat Bacterial Infections
    Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service Medicines to treat bacterial infections This brochure contains some information on Important: Antibiotic resistance can the medicines you may have been prescribed affect us all. to treat a bacterial infection either in hospital or on discharge. Please talk to your doctor or Help limit the development of antibiotic pharmacist if you would like more information resistance by using antibiotics correctly. on a specific antibiotic. Make sure you: Take antibiotics exactly as prescribed. What is an antibiotic? • Antibiotics are medicines used to treat • Follow instructions on how many times a infections caused by bacteria. They are not day and for how long to take them. effective against viral infections such as the • Do not stop treatment early, even if you common cold and the ‘flu’. feel better. Medicine Other information Amoxicillin May be taken with or without food. Amoxicillin/ Take with the first bite of a meal. clavulanic acid Cefalexin May be taken with or without food. Take on an empty stomach with a glass of water, 1 hour before or 2 hours after food. Ciprofloxacin Do not take dairy products, antacids, iron, zinc or calcium within 2 hours of the dose. Clindamycin Take with a full glass of water. May be taken with or without food. Take with food or milk. Remain upright for an hour after dose to prevent damage to the Doxycycline lining of your throat. Do not take dairy products, antacids, iron, zinc or calcium within 2 hours of the dose. Take on an empty stomach, 1 hour before or 2 hours after food.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update
    Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update Aline Fuchsa, Julia Bielickia,b, Shrey Mathurb, Mike Sharlandb, Johannes N. Van Den Ankera,c a Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland b Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom c Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA WHO-Reviews 1 TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................................................... 3 1.1. Aims ......................................................................................................................................... 3 1.2. Background ............................................................................................................................. 3 1.2.1. Definition and diagnosis ................................................................................................. 3 Neonatal Sepsis ............................................................................................................................... 3 Paediatric Sepsis ............................................................................................................................. 4 Community versus hospital acquired sepsis .................................................................................. 5 1.2.2. Microbiology ..................................................................................................................
    [Show full text]
  • Antibiotic Dosing for Children: Draft Expert Recommendations for the 2017 Essential Medicines List for Children (Emlc)
    Antibiotic Dosing for Children: Draft expert Recommendations for the 2017 Essential Medicines List for Children (EMLc) Purpose and Scope of Recommendations Expert recommendations for antibiotic dosing in the EMLc have been developed to address the lack of harmony in currently available international formularies. In many instances, recommendations are historical practise-based and not strongly evidence-based. Limited evidence is available from studies of effectiveness and safety as well as all age pharmacokinetics for children. National preferences for weight-based (US), age-banded (UK) and weight-banded (WHO) dosing strategies have resulted in quite widely varying recommendations. The rationale of this dosing guidance has been to provide simple recommendations which are feasible in the LMIC context. Dosing guidance has been given as a single total daily dose (mg/kg/day) with options for acceptable frequency of dosing which can be adapted to local context. A maximum upper dose has been provided, largely based on available adult dosing. These recommendations have been developed for children ages 2 months to 12 years. In general, the aim was to produce a simple dosing guidance that covered all clinical infection syndromes, except severe infections such as meningitis, where significantly higher doses are recommended. Dosing recommendations have not been adjusted for children with renal or liver impairment. The recommendations have not accounted for global variation in rates of antimicrobial resistance. Using a single dose in this overall guidance does not reflect the range of doses that are actually required to translate the guidance into practical weight/age based formulations for children. Methods For the development of these recommendations, the expert group comprised paediatricians, paediatric clinical pharmacologists and pharmacists based in the UK and Europe.
    [Show full text]
  • Assessment of Antibiotic Treatment of Cellulitis and Erysipelas a Systematic Review and Meta-Analysis
    Research JAMA Dermatology | Original Investigation Assessment of Antibiotic Treatment of Cellulitis and Erysipelas A Systematic Review and Meta-analysis Richard Brindle, DM, FRCP; O. Martin Williams, PhD, FRCP, FRCPath; Edward Barton, BM, FRCPath; Peter Featherstone, MPhil, FRCP Supplemental content IMPORTANCE The optimum antibiotic treatment for cellulitis and erysipelas lacks consensus. The available trial data do not demonstrate the superiority of any agent, and data are limited on the most appropriate route of administration or duration of therapy. OBJECTIVE To assess the efficacy and safety of antibiotic therapy for non–surgically acquired cellulitis. DATA SOURCES The following databases were searched to June 28, 2016: Cochrane Central Register of Controlled Trials (2016, issue 5), Medline (from 1946), Embase (from 1974), and Latin American and Caribbean Health Sciences Information System (LILACS) (from 1982). In addition, 5 trials databases and the reference lists of included studies were searched. Further searches of PubMed and Google Scholar were undertaken from June 28, 2016, to December 31, 2018. STUDY SELECTION Randomized clinical trials comparing different antibiotics, routes of administration, and treatment durations were included. DATA EXTRACTION AND SYNTHESIS For data collection and analysis, the standard methodological procedures of the Cochrane Collaboration were used. For dichotomous outcomes, the risk ratio and its 95% CI were calculated. A summary of findings table was created for the primary end points, adopting the GRADE approach to assess the quality of the evidence. MAIN OUTCOMES AND MEASURES The primary outcome was the proportion of patients cured, improved, recovered, or symptom-free or symptom-reduced at the end of treatment, as reported by the trial.
    [Show full text]
  • PATIENT INFORMATION LEAFLET CEFALEXIN 250 Mg and 500 Mg
    PATIENT INFORMATION LEAFLET CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What these capsules are and what they are used for 2. Before you take these capsules 3. How to take these capsules 4. Possible side effects 5. How to store these capsules 6. Further information 1. WHAT THESE CAPSULES ARE AND WHAT THEY ARE USED FOR Cefalexin capsules contain the active ingredient cefalexin, which is an antibiotic. Antibiotics work by killing the bacteria (germs) that can cause an infection. Cefalexin Capsules are used to treat the following infections: the lungs and breathing airways (bronchitis and mild to moderate pneumonia) the skin and soft tissue (such as wound infection) 2. BEFORE YOU TAKE THESE CAPSULES Do not take these capsules if: you are allergic (hypersensitive) to cefalexin other cephalosporins (similar antibiotics) or any of the other ingredients of these capsules (see list of ingredients in section 6) An allergic reaction may include rash, itching, difficulty breathing or swelling of the face, lips, throat or tongue. Take special care with these capsules if you: have had an allergic reaction to cefalexin, cephalosporins, penicillins or other drugs develop diarrhoea have a severe kidney disorder (you may need a reduced dose) If any of the above applies to you, speak to your doctor.
    [Show full text]
  • Cefalexin (Ceporex) 500Mg Capsules: Each Capsule Contains 500Mg Cefalexin
    Cefalexin Ceporex Oral Preparations PRODUCT DESCRIPTION Cefalexin (Ceporex) 500mg Capsules: Each capsule contains 500mg Cefalexin. The capsule is Size #0 hard gelatine capsule with an opaque caramel coloured body printed with GS 3ZI axially in white ink and a plain opaque dark grey cap containing white to yellowish white powder. It contains Magnesium stearate as an excipient. Cefalexin (Ceporex) 125mg/5mL Powder for Suspension: Each 5 ml of constituted suspension contains 125 mg of cefalexin. Excipients include Sodium calcium edetate, Acacia, Orange Bramble Flavour SO 370, Polvaromas, Citric Acid BP anhydrous 100-Mesh, Sodium citrate anhydrous, Sunset Yellow Ariavit, Caster sugar, Icing sugar. The powder prior to reconstitution has a pale pink coarse powder with characteristic odour. Cefalexin (Ceporex) 250mg/5mL Powder for Suspension: Each 5 ml of constituted suspension contains 250 mg of cefalexin. Excipients include Sodium calcium edetate, Acacia, Orange Bramble Flavour SO 370, Polvaromas, Citric Acid BP anhydrous 100-Mesh, Sodium citrate anhydrous, Sunset Yellow Ariavit, Caster sugar, Icing sugar. The powder prior to reconstitution has a pale pink coarse powder with characteristic odour. Cefalexin (Ceporex) Powder for Suspension (Oral Drops): Each 1 ml of constituted drops contains 100 mg of cefalexin. Excipients include Sodium calcium edetate, Acacia, Orange Bramble Flavour SO 370, Polvaromas, Citric Acid BP anhydrous 100-Mesh, Sodium citrate anhydrous, Sunset Yellow Ariavit, Caster sugar. The powder prior to reconstitution gives a pale pink to orange granules with a characteristic odour. PHARMACOLOGICAL PROPERTIES Mechanism of Action Cefalexin is an oral broad- spectrum antibiotic. In adequate concentrations it is bactericidal for sensitive proliferating microorganisms by inhibiting the biosynthesis of the cell wall.
    [Show full text]
  • Amendment of AWARE Antibiotic Classification
    Amendment of AWARE antibiotic classification The current AWARE classification includes three categories ACCESS, WATCH and RESERVE. However, there are several antibiotics/antibiotic classes that are not included in the existing three categories. These are currently classified as “OTHER”. To address this issue, the EML Secretariat is proposing to amend the classification to include the following antibiotics into the three existing categories with goal of reflecting the 2019 EML Committee potential decisions and providing clarification to enhance the potential Stewardship interventions under development using AWARE. Using the WHO ATC antibiotics that are not classified into existing three categories are identified. Second generation cephalosporins: This class will be categorized into “WATCH” group. This is based on the EML application for surgical prophylaxis (which will be discussed in April), where cefuroxime, a second-generation cephalosporin is first choice (pending approval from the committee). However, considering the selection for ESBL organisms and increased risk of C. difficile when compared to first generation cephalosporins this antibiotic is suggested for inclusion in WATCH category. As cefuroxime is representative of second generation cephalosporins, other antibiotics in this class will also be included in the WATCH category. Fixed dose combinations (FDCs): There are limited number of FDCs approved by WHO and US FDA. However, there are several FDCs available in LMICs. We suggest that these FDCs not approved by WHO and US FDA should be placed in a separate classification of “Not Supported by the EML”. Aminoglycosides other than gentamicin and amikacin: These will be categorized as WATCH group considering the lack of indication as first-line of these agents.
    [Show full text]
  • Guidelines on Urological Infections
    Guidelines on Urological Infections M. Grabe (Chairman), T.E. Bjerklund-Johansen, H. Botto, M. Çek, K.G. Naber, P. Tenke, F. Wagenlehner © European Association of Urology 2010 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urological infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guideline recommendations 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Definition 11 2.1.1 Aetiological spectrum 11 2.2 Acute uncomplicated cystitis in premenopausal, non-pregnant women 11 2.2.1 Diagnosis 11 2.2.1.1 Clinical diagnosis 11 2.2.1.2 Laboratory diagnosis 11 2.2.2 Therapy 11 2.2.3 Follow up 12 2.3 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 12 2.3.1 Diagnosis 12 2.3.1.1 Clinical diagnosis 12 2.3.1.2 Laboratory diagnosis 12 2.3.1.3 Imaging diagnosis 13 2.3.2 Therapy 13 2.3.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 13 2.3.2.2 Severe cases of acute uncomplicated pyelonephritis 13 2.3.3 Follow-up 14 2.4 Recurrent (uncomplicated) UTIs in women 16 2.4.1 Diagnosis 16 2.4.2 Prevention 16 2.4.2.1 Antimicrobial prophylaxis 16 2.4.2.2 Immunoactive prophylaxis 16 2.4.2.3 Prophylaxis with probiotics 17 2.4.2.4 Prophylaxis with cranberry 17 2.5 Urinary tract infections in pregnancy 17 2.5.1 Definition of significant bacteriuria 17 2.5.2 Screening 17 2.5.3 Treatment of asymptomatic bacteriuria 17 2.5.4 Duration of therapy 18 2.5.5 Follow-up 18 2.5.6 Prophylaxis 18 2.5.7 Treatment of pyelonephritis 18 2.5.8 Complicated UTI 18 2.6 UTIs in postmenopausal women 18 2.6.1 Risk factors 18 2.6.2 Diagnosis 18 2.6.3 Treatment 18 2.7 Acute uncomplicated UTIs in young men 19 2.7.1 Men with acute uncomplicated UTI 19 2.7.2 Men with UTI and concomitant prostate infection 19 2.8 Asymptomatic bacteriuria 19 2.8.1 Diagnosis 19 2.8.2 Screening 19 2.9 References 26 3.
    [Show full text]
  • Antibacterial Use in Our Practice the Antibiotic Guardian(S) of This Practice Is/Are
    Antibacterial use in our practice The antibiotic guardian(s) of this practice is/are: Select which antibacterials your practice EYE INFECTIONS ORAL INFECTIONS RESPIRATORY INFECTIONS uses in the boxes below ADVERSE REACTIONS TO ANTIBACTERIALS Canine conjunctivitis: Consider chlorhexidine mouthwash Antibacterials are not indicated for: ■ Chronic bronchitis/allergic airway disease unless secondarily infected Culture essential to ensure e ective Fusidic acid This list is not comprehensive. Severe gingivitis and periodontitis: ■ rescribe only when necessary Chlortetracycline Canine sino-nasal disease P therapy Amoxicillin/clavulanate ■ Consider non-bacterial disease (e.g. viral infection, Treat for 5–7 days Metronidazole Canine infectious respiratory disease complex (Kennel Cough) and Feline Antimicrobial Adverse e ect At risk group Recommendation upper respiratory tract infection (Cat Flu): nutritional imbalance, metabolic disorders) Culture strongly advised to guide therapy Feline conjunctivitis: Clindamycin (if periodontal bone infections) ONLY if clinical signs present >10 days and/or systemically unwell Aminoglycosides Nephrotoxicity Dogs/cats with Avoid in at risk ■ Remember that some bacterial diseases will self-resolve (where possible) pre-existing animals or when close Chlortetracycline Ulcerative stomatitis: Doxycycline without antibacterials renal disease, monitoring is not Fusidic acid ■ O er a non-prescription form (see box bottom right) Use your smartphone and a QR code Metronidazole Amoxicillin/clavulanate volume or available
    [Show full text]